Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take aim at myasthenia gravis

NCT ID NCT04146051

Disease control Sponsor: Cartesian Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This Phase 2 trial is testing an experimental therapy called Descartes-08 for people with generalized myasthenia gravis, a condition that causes muscle weakness. Descartes-08 uses a patient's own immune cells, engineered to target and potentially reduce the harmful immune cells that drive the disease. The study will evaluate the safety and effectiveness of this approach, comparing it against a placebo in some participants.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Descartes-08, a personalized CAR T-cell therapy that targets BCMA on immune cells
What this could lead to
If successful, this could offer a new treatment option for generalized myasthenia gravis, potentially reducing symptoms and improving quality of life.
What could go wrong
This is an early-stage trial with a small number of participants. The therapy may not work for everyone, and there are risks associated with CAR T-cell treatments, such as immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2019

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient must be at least 18 years of age. * Patient must have Generalized Myasthenia Gravis at the time of screening. * Concomitant immunosuppressive drugs must be deemed necessary by the investigator. * Seronegative Patients are included Exclusion Criteria: * Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator may increase the risk to the patient. * Patient is pregnant or lactating.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myasthenia gravis, generalized are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myasthenia gravis, generalized

Contacts and locations

Locations

  • Allegheny Health Network

    Pittsburgh, Pennsylvania, 15212, United States

  • Dent Neurologic Institute

    Amherst, New York, 14226, United States

  • Neurology Associates, P.A.

    Orlando, Florida, 32751, United States

  • Oregon Health & Science University

    Portland, Oregon, 97239, United States

  • Profound Research

    Carlsbad, California, 92011, United States

  • SFM Clinical Research, LLC

    Boca Raton, Florida, 33487, United States

  • University of Alberta

    Edmonton, Alberta, T6G2C8, Canada

  • University of Augusta

    Augusta, Georgia, 30912, United States

  • University of California Irvine

    Irvine, California, 92697, United States

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado, 80045, United States

  • University of Kansas Medical Center Research Institute

    Kansas City, Kansas, 66160, United States

  • University of North Carolina

    Chapel Hill, North Carolina, 27599, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • University of South Florida

    Tampa, Florida, 33612, United States

  • Virginia Commonwealth University

    Richmond, Virginia, 23219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.